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JordanAbstract The adipose tissue is not only an inert storage depot for lipids, but also it secretes a vari-
ety of bioactive molecules, known as adipokines, which affect whole-body homeostasis. Adiponec-
tin is the most abundant of these adipocytokines and is known to have a regulatory effect on the
metabolism of glucose and lipid. The main objectives of this study were to evaluate the serum levels
of adiponectin and to establish a correlation between adiponectin serum levels and the degree of
insulin resistance in type 2 diabetic patients. Eighty participants were enrolled in this study; 61 type
2 diabetic patients and 19 apparently healthy subjects. Serum level of adiponectin was measured by
enzyme-linked immunosorbent assay (ELISA) for each participant. Data collection sheet was ﬁlled
with all required information for each participant. Adiponectin level in the diabetic patients
(5.05 ± 2.61 lg/ml) was lower than in non-diabetic healthy controls (5.71 ± 2.35 lg/ml). When
the results were compared according to gender, diabetic females showed signiﬁcantly higher adipo-
nectin levels (5.76 ± 2.64 lg/ml) than diabetic males (4.366 ± 2.43 lg/ml, P= 0.035). In addition,
female diabetic patients with abdominal obesity (waist circumference (WC)P 88 cm) had lower
adiponectin levels (5.58 ± 2.58 lg/ml) than diabetic females without abdominal obesity
(6.96 ± 3.12 lg/ml). The correlation analysis indicated that adiponectin had a signiﬁcant positive
correlation with age (r= 0.450, P< 0.001). In conclusion, female diabetic patients had a statis-
tically signiﬁcant higher adiponectin level than male diabetic patients which could indicate a gender
Adiponectin serum levels correlate with insulin resistance 251effect. Adiponectin levels were inversely related to insulin resistance; as patients with abdominal
obesity had lower serum levels of adiponectin.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The designation of the adipose tissue as a pivotal active endo-
crine organ has indeed drawn much scientiﬁc interest in the
last few years. The adipose tissue is now viewed as the largest
endocrine organ in the body (Oh et al., 2007). It secretes
numerous bioactive proteins, collectively known adipocytes,
into the circulation (Chandran et al., 2003). The most abun-
dant of these adipocytokines is the adiponectin which is
secreted by white adipose tissue and accounts for 0.01% of
total plasma proteins (Gil-Campos et al., 2004; Heiker
et al., 2010).
Adiponectin shares homology with collagen and comple-
ment 1q family (Simpson and Whitehead, 2010). It consists
of 244 amino acids, which form four different domains
(Sheng and Yang, 2008). Adiponectin modulates a number
of metabolic processes via the activation of 50-adenosine
monophosphate-activated protein kinase (AMPK) and perox-
isome proliferator activated receptor-a (PPAR-a) (Fagerberg
et al., 2011). In addition, it plays an important role in the sup-
pression of the metabolic derangements that cause insulin
resistance and type 2 diabetes mellitus (type 2 DM) (Sheng
and Yang, 2008).
Interestingly, although adiponectin is secreted by mature
adipocytes, its plasma level shows a negative correlation with
body fat mass. It has been found that adiponectin plasma
level in obese individuals was lower than in non-obese ones
(Arita et al., 2012). Adiponectin has been also shown to be
negatively correlated with obesity-related diseases such as
type 2 DM (Han et al., 2009). Furthermore, low adiponectin
levels predicts the incidence of type 2 DM (Han et al., 2009).
The latter ﬁndings have triggered a wealth of studies aiming
at investigating the impact of circulating plasma adiponectin
levels on enhancing insulin sensitivity in the diabetic patients
(Fagerberg et al., 2011; Nayak et al., 2010; Weyer et al.,
2001).
Diabetes types 2 as well as the impaired fasting glucose
(IFG) are common among Jordanian population. The esti-
mated age standardized prevalence rate of (IFG) and diabetes
were 7.8% and 17.1%, respectively, with no signiﬁcant gender
differences according to a recent study (Ajlouni et al., 2008).
To complicate things further, there are alarming rates of obes-
ity and its associated co-morbidities among Jordanians, espe-
cially among women (Khader et al., 2008). This study aims
to evaluate the serum levels of adiponectin in type 2 diabetic
patients and to establish a correlation between adiponectin
serum levels and insulin resistance in those patients. In
contrast, previous studies had investigated the association of
adiponectin serum levels and obesity and DM type 2. Jordan
is an ideal place to conduct the current study due to the high
prevalence of DM type 2 and prediabetes, as mentioned
earlier.2. Methods
2.1. Setting and participants
This is a cross-sectional study that has been conducted in the
outpatient diabetes clinic of National Center for Diabetes,
Endocrinology, and Genetics for 7 months. Eighty Jordanian
subjects were included; 61 patients above 18 years diagnosed
with type 2 diabetes for at least 6 months and 19 apparently
healthy, medically free, and treatment naive individuals were
recruited to serve as non-diabetic control. Type 1 diabetic
patients, patients with acute or chronic kidney disease, patients
with congestive heart failure, patients receiving thiazolidinedi-
one (TZD) or exogenous insulin, and pregnant female patients
all were excluded from the study.
Sample size calculation was conducted using an online tool
(The Survey System, Creative Research Systems, www.survey-
system.com). Using a conﬁdence level of 95%, a minimum
sample size of 79 subjects was calculated to be sufﬁcient to
conduct the study. An Institutional Review Board (IRB)
approval was granted and an informed consent form, written
in lay Arabic language, was handed to and signed by each
subject.
2.2. Anthropometric measurements
All the anthropometric parameters including weight, height,
and waist circumference (WC) were measured in a situation
where subjects were in the standing position and wearing light
clothing without shoes.
WC was measured in centimeters using constant tension
tape at the end of a normal expiration at the point between
the rib cage and the pelvis. Abdominal obesity was deﬁned
as WCP 102 cm in males and P88 cm in female.
Body weight was measured in kilograms to the nearest
0.5 kg using a calibrated balance. Height was measured in
centimeters to the nearest 0.5 cm. Body mass index (BMI)
for each subject was calculated as body weight (in kilograms)
divided by the square of body height (in meters). The
BMI was classiﬁed into normal (8–24.9 kg/m2), overweight
(25–29.9 kg/m2), obese (30–34.9 kg/m2) and morbidly obese
(>35 kg/m2).
2.3. Sample collection and handling
Venous blood samples (6–8 ml) were collected in sterile plain
tubes from all subjects after fasting for at least 10 h. Serum
samples were separated by centrifugation of the coagulated
blood samples at 4000 rpm for 5 min at 4 C and then ali-
quoted and stored at 80 C until the day of adiponectin level
measurement using (ELIZA).
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Serum adiponectin concentration was measured using a com-
mercially available human ELIZA kit (Adipo Bioscience,
USA, Adipo Bioscience Incorporation, 2012).
The ELISA assay utilizes a monoclonal puriﬁed immuno-
globulin G (IgG) against a speciﬁc determinant on human
adiponectin molecule for capture on the micro plate wells
and a mouse anti-adiponectin antibody conjugated to horse-
radish peroxidase (HRP) for detection. The serum samples
were thawed at room temperature and then they were
diluted by 5000 folds using dilution buffer supplied by the
kit. 100 lL of diluted serum were added to each plate well.
The assay was carried out according to the manufacturer
procedures (Adipo Bioscience, USA). The developed color
was measured spectrophotometrically using the micro plate
reader (MQX200, Biotek, USA) at 450 nm. Adiponectin
concentrations, in lg/ml, were calculated from the standard
curve prepared using recombinant human adiponectin
standards.
2.5. Data management and statistical analysis
All data were processed using the statistical package for
social science (SPSS version 16, Chicago, USA software).
Differences were considered statistically signiﬁcant if
P< 0.05. Continuous variables were expressed as
mean ± SD while categorical variables were presented as per-
centage. For testing whether there was a normal distribution
or not, Kolmogorov–Smirnov test was used. For comparison
of two normally distributed means t-test was used. If distri-
bution of variables was not normal, the statistical analysis
was conducted using Kruskall–Wallis followed by Mann–
Whitney. Continuous variables were compared using stu-
dent’s t-test.
Chi-square was used to compare categorical variables.
Pearson correlation coefﬁcients were calculated to evaluate
the relationship between serum adiponectin levels and study
variables.Table 1 Clinical and demographic characteristics of the study pop
Parameter Diabetic patients, N (%)
61 (76.25)
Agea (year) 56.15 ± 12.02
Genderb
Male 31 (50.8)
Female 30 (49.2)
Smoking status
Smoker 19 (31.1)
Non-smoker 42 (68.9)
BMIa (kg/m2) 28.36 ± 3.47
WCa (cm) 97.79 ± 9.22
Adiponectina (lg/ml) 5.05 ± 2.61
Abbreviations: BMI – body mass index; WC – waist circumference; N –
a Data were presented as means ± SD and t-test used for comparison.
b Data were presented as percentage and compared via chi-square test.3. Results
The clinical and demographic characteristics of the study pop-
ulation are presented in Table 1. In the study population, dia-
betic patients had lower adiponectin serum level compared to
non-diabetics control group. However, statistically this differ-
ence was not signiﬁcant (Fig. 1A).
3.1. Association of adiponection with obesity (abdominal and
general obesity), impact of gender
Interestingly, there was a statistically signiﬁcant gender differ-
ence in adiponectin serum level among the study population.
Diabetic females showed signiﬁcantly high adiponectin serum
level in contrast to diabetic males (5.76 ± 2.64 lg/ml versus
4.366 ± 2.43 lg/ml, respectively, P= 0.035) (Fig. 1B). In
order to investigate this ﬁnding further, diabetic patients were
classiﬁed according to the gender and the prevalence of the
abdominal obesity into two groups: patients with abdominal
obesity, which is a marker of insulin resistance, and patients
without (Tables 2 and 3).
The results showed that abdominal obesity is associated
with low circulating adiponectin levels in both genders. More-
over, when compared across gender, adiponectin level was
higher in diabetic females with abdominal obesity than in
males (Tables 2 and 3). Adiponectin serum levels correlated
negatively with both WC and BMI in diabetic patients
(Pearson correlation coefﬁcient (r) = 0.125 and 0.222,
respectively). However, these correlations were not statistically
signiﬁcant (p 0.337 and 0.086, respectively). As a measure for
general obesity, diabetic patients were classiﬁed according to
their BMI into two categories (obese and non-obese). Both
normal weight and overweight patients were grouped under
the ‘‘non-obese’’ patients group. Obese patients had a lower
adiponectin serum level compared to non-obese patients, but
statistically the difference was not signiﬁcant (4.57 ± 2.23
lg/ml versus 5.38 ± 2.83 lg/ml, P= 0.416). On the other
hand, serum adiponectin levels correlated positively with age
(Pearson correlation (r) = 0.450, P< 0.001).ulation.
Control group, N (%) P-value
19 (23.75)
43.05 ± 9.19 0.001
12 (63.2) 0.346
7 (36.8)
6 (31.6) 0.972
13 (68.4)
26.47 ± 3.52 0.043
96.00 ± 7.79 0.447
5.71 ± 2.35 0.331
number of subjects.
Figure 1 Box and whisker plot plots of adiponectin serum levels in different subject groups. (A) Adiponectin serum levels in diabetic and
non-diabetic. (B) Adiponectin serum levels in diabetic females and males.
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patients
The majority of patients (70.5%) had adiponectin serum levels
within (1.02–6.9 lg/ml) while (29.5%) had adiponectin levels
P7 lg/ml (Fig. 2 and Table 4). In order to justify this ﬁnding,
diabetic patients were divided into two groups according to the
variance in adiponectin levels. A cut off value of 7 lg/ml was
arbitrarily chosen (Semple et al., 2008) to designate a non-
reduced level of adiponectin. Table 4 shows comparisons
between these two groups. There was a statistically signiﬁcantdifference in age and gender between the two groups
(P< 0.05). The majority of diabetic patients who had adipo-
nectin serum levelP7 lg/ml were females (72%). Interestingly,
patients in this group had lower mean of BMI than patients in
the group of patients who had adiponectin serum level 67 lg/
ml (Table 4).
4. Discussion
This study, as a few other series studies, has investigated
adiponectin levels among type 2 diabetic patients. We have
Table 2 Adiponectin levels in Female diabetic patients according to the abdominal obesity prevalence.
Diabetic females with abdominal obesitya Diabetic females without abdominal obesitya P-value
N (%) 26 (86.7) 4 (13.3)
Adiponectinb (lg/ml) 5.58 ± 2.58 6.96 ± 3.12 0.882
a Abdominal obesity was deﬁned as WCP 102 cm in females.
b Data were presented as means ± SD and t-test used for comparison.
Table 3 Adiponectin levels in Male diabetic patients according to the abdominal obesity prevalence.
Diabetic males with abdominal obesitya Diabetic males without abdominal obesitya P-value
N (%) 12 (38.7) 19 (61.3)
Adiponectinb (lg/ml) 4.28 ± 2.22 4.42 ± 2.61 0.882
a Abdominal obesity was deﬁned as WCP 102 cm in males.
b Data were presented as means ± SD and t-test used for comparison.
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assessing the levels of adiponectin and its correlation with
waist circumference. The latter is an important determinant
for insulin resistance.
Females had a signiﬁcantly higher adiponectin serum levels
than males. A possible explanation for this gender based dif-
ference in adiponectin serum levels might be due to the
following reasons; ﬁrst, is the effect of sex hormones on the
production of adiponectin rate (Kadowaki et al., 2006). Exper-
imental studies have proved that androgens have an inhibitory
effect on adiponectin secretion (Bottner et al., 2004; Nishizawa
et al., 2002). Second, is the different body fat distribution
between males and females. It has been reported that the
number of fat cells and their size are possible determinantsFigure 2 The distribution of adiponecof adiponectin production rates since it is mainly secreted from
adipocytes (Cnop et al., 2003).
It is known that insulin resistance increases with age, which
would predict the lower adiponectin levels in the elderly (Cnop
et al., 2003). Interestingly, our study has shown that the adipo-
nectin levels were correlated positively with age. The increase
in adiponectin levels with age could be explained by the fact
that the decline in sex steroidal hormones with age might rise
the adiponectin levels in the elderly (Bottner et al., 2004;
Nishizawa et al., 2002). Moreover, the decline in renal function
with aging might reduce the adiponectin clearance by kidney
(Isobe et al., 2005).
Generally, obesity is associated with insulin resistance
(Cnop et al., 2002). Abdominal obesity, where the fat istin serum levels in diabetic patients.
Table 4 Diabetic patients according to the variance in adiponectin levels.
Variable Diabetic patients with adiponectin
level < 7 lg/ml
Diabetic patients with adiponectin
levelP 7 lg/ml
P-value
N (%) 43(70.5) 18 (29.5)
Age (year)a 52.93 ± 11.51 63.83 ± 9.68 0.001
Genderb
Female 17(39.5) 13 (72.2) 0.020
Male 26(60.5) 5 (27.8)
BMIa (kg/m2) 28.91 ± 3.47 27.0 ± 3.18 0.054
WCa (cm) 98.98 ± 8.92 95.06 ± 9.59 0.135
Abbreviations: BMI – body mass index; WC – waist circumference; N – number of subjects.
a Data were presented as means ± SD and t-test used for comparison.
b Data were presented as percentage and compared via chi-sequre test.
Adiponectin serum levels correlate with insulin resistance 255centrally distributed, is particularly an important determinant
of insulin resistance (Cnop et al., 2003; Gierach et al., 2014). It
has been reported that abdominal obesity, measured by waist
circumferences, is strongly associated with lower levels of
adiponectin and decrease in insulin sensitivity among diabetic
patients (Cnop et al., 2003; Mohammadzadeh and Ghaffari,
2014).
This study has shown low levels of adiponectin in both
obese diabetic patients and patients with abdominal obesity
and negative correlation between adiponectin levels and both
BMI and WC. Given the fact that adiponectin is a major
modulator of insulin action for its role in enhancing insulin
sensitivity (Cnop et al., 2003; Schulze et al., 2004), it is there-
fore of critical importance to note that factors decreasing
adiponectin levels such as obesity, and specially the abdominal
obesity, could correlate with insulin resistance.
In addition, diabetic patients included in this study had a
variable adiponectin serum levels. The majority of them had
levels between (1.02–6.9) lg/ml while the remaining had levels
P7 lg/ml. This variability in adiponectin serum levels might
indicate that there are some factors affect the adiponectin lev-
els among type 2 diabetic patients. It is important to note that
the majority of diabetic patients who have adiponectin levels
P7 lg/ml were elderly, females, and had lower mean of BMI
compared to the second group (Table.4). Taken together, these
characteristics of diabetic patients who have adiponectin levels
P7 lg/ml are possible factors for increasing adiponectin level
in this subgroup of diabetic patients.
Semple et al., 2008 have found that adiponectin levels more
than 7 lg/ml are associated with severe insulin resistance and
has a 97% positive predictive value for insulin receptoropathy
(Semple et al., 2008). While adiponectin levels less than
5 lg/ml have a 97% negative predictive value for insulin recep-
toropathy (Semple et al., 2008). It was suggested that patients
with insulin receptor dysfunction, including diabetics, may
have unexpectedly high levels of adiponectin (Semple et al.,
2008).
Interestingly, a series of published studies have reported a
paradoxical high level of adiponectin in diabetic patients with
severe insulin resistance (Semple et al., 2008, 2007, 2006). This
paradoxical hyperadiponectinemia is due to pathology in the
insulin receptor ‘‘insulin receptoropathy’’ which occurs in
select patients (Semple et al., 2008). In those patients, insulin
resistance was caused either by mutation in the receptor or
by auto antibodies against the receptor (Semple et al., 2008).In fact, experimental studies have showed that in knockout
mice with adipose-speciﬁc deletion of the insulin receptor,
there was as much as 60% increase in the serum adiponectin
levels (Bluher et al., 2002). The latter ﬁnding clearly delineates
a potential role for adiponectin in modulating the interaction
between insulin and its receptor.
This ﬁnding indicates that the net effect on insulin resis-
tance will be determined by the contribution of a constellation
of factors that dictate the molecular interaction between
insulin and its receptor in different effector tissues and organs.
5. Conclusion
Adiponectin could link intra-abdominal fat with insulin resis-
tance. Gender and age are independent predictors of serum
adiponectin levels and thus they need to be taken into
account when assessing the level of adiponectin. This poten-
tial correlation between adiponectin levels and insulin resis-
tance is a ﬁrst step in establishing new treatment strategies
and monitoring parameters in our ﬁght against diabetes.
The idea of using adiponectin serum level as a marker for
both predicting and monitoring the proper therapeutic
regimens in type 2 diabetic patients is highly plausible.
Further studies are still needed to unravel the full therapeutic
potential and clinical applications of adiponectin in the
management of diabetes.
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